

J R Chalmers

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3487846/publications.pdf>

Version: 2024-02-01

79
papers

3,519
citations

201674

27
h-index

144013

57
g-index

80
all docs

80
docs citations

80
times ranked

3124
citing authors

#	ARTICLE	IF	CITATIONS
1	Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. Journal of Allergy and Clinical Immunology, 2014, 134, 818-823.	2.9	594
2	The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials. Journal of Allergy and Clinical Immunology, 2014, 134, 800-807.	2.9	257
3	The Harmonizing Outcome Measures for Eczema (HOME) Roadmap: A Methodological Framework to Develop Core Sets of Outcome Measurements in Dermatology. Journal of Investigative Dermatology, 2015, 135, 24-30.	0.7	184
4	Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet, The, 2020, 395, 962-972.	13.7	178
5	Towards global consensus on outcome measures for atopic eczema research: results of the <scp>HOME II</scp> meeting. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 1111-1117.	5.7	169
6	Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. Lancet, The, 2017, 389, 1630-1638.	13.7	167
7	Penicillin to Prevent Recurrent Leg Cellulitis. New England Journal of Medicine, 2013, 368, 1695-1703.	27.0	149
8	Patient-Oriented Eczema Measure (POEM), a core instrument to measure symptoms in clinical trials: a Harmonising Outcome Measures for Eczema (HOME) statement. British Journal of Dermatology, 2017, 176, 979-984.	1.5	141
9	Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative). British Journal of Dermatology, 2016, 175, 69-79.	1.5	115
10	Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative). British Journal of Dermatology, 2018, 178, e332-e341.	1.5	96
11	Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME). British Journal of Dermatology, 2014, 171, 1318-1325.	1.5	95
12	Evaluation of the measurement properties of symptom measurement instruments for atopic eczema: a systematic review. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 146-163.	5.7	71
13	Prophylactic antibiotics for the prevention of cellulitis (erysipelas) of the leg: results of the U.K. Dermatology Clinical Trials Network's PATCH II trial. British Journal of Dermatology, 2012, 166, 169-178.	1.5	65
14	Measurement properties of adult quality of life measurement instruments for eczema: a systematic review. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 358-370.	5.7	56
15	Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (The BEEP trial): protocol for a randomised controlled trial. Trials, 2017, 18, 343.	1.6	56
16	Development and initial testing of a new instrument to measure the experience of eczema control in adults and children: Recap of atopic eczema (<scp>RECAP</scp>). British Journal of Dermatology, 2020, 183, 524-536.	1.5	52
17	Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting*. British Journal of Dermatology, 2021, 185, 139-146.	1.5	52
18	The HOME Core outcome set for clinical trials of atopic dermatitis. Journal of Allergy and Clinical Immunology, 2022, 149, 1899-1911.	2.9	51

#	ARTICLE	IF	CITATIONS
19	Association of frequent moisturizer use in early infancy with the development of food allergy. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 967-976.e1.	2.9	50
20	Navigating the landscape of core outcome set development in dermatology. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 297-305.	1.2	46
21	What Factors are Important to Patients when Assessing Treatment Response: An International Cross-sectional Survey. <i>Acta Dermato-Venereologica</i> , 2017, 97, 86-90.	1.3	45
22	Report from the kick-off meeting of the Cochrane Skin Group Core Outcome Set Initiative (CSG-COUSIN). <i>British Journal of Dermatology</i> , 2016, 174, 287-295.	1.5	41
23	A functional mechanistic study of the effect of emollients on the structure and function of the skin barrier. <i>British Journal of Dermatology</i> , 2016, 175, 1011-1019.	1.5	39
24	Skincare interventions in infants for preventing eczema and food allergy: A cochrane systematic review and individual participant data meta-analysis. <i>Clinical and Experimental Allergy</i> , 2021, 51, 402-418.	2.9	38
25	Skin care interventions in infants for preventing eczema and food allergy. <i>The Cochrane Library</i> , 2021, 2021, CD013534.	2.8	37
26	Strategies used for measuring long-term control in atopic dermatitis trials: A systematic review. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 1038-1044.	1.2	35
27	Reporting of symptoms in randomized controlled trials of atopic eczema treatments: a systematic review. <i>British Journal of Dermatology</i> , 2016, 175, 678-686.	1.5	34
28	Safety of topical corticosteroids in atopic eczema: an umbrella review. <i>BMJ Open</i> , 2021, 11, e046476.	1.9	32
29	Prophylactic Antibiotics to Prevent Cellulitis of the Leg: Economic Analysis of the PATCH I & II Trials. <i>PLoS ONE</i> , 2014, 9, e82694.	2.5	30
30	“When it goes back to my normal I suppose”: a qualitative study using online focus groups to explore perceptions of “control” among people with eczema and parents of children with eczema in the UK. <i>BMJ Open</i> , 2017, 7, e017731.	1.9	30
31	Core outcome sets in dermatology: report from the second meeting of the International Cochrane Skin Group Core Outcome Set Initiative. <i>British Journal of Dermatology</i> , 2018, 178, e279-e285.	1.5	29
32	Measuring atopic eczema symptoms in clinical practice: The first consensus statement from the Harmonising Outcome Measures for Eczema in clinical practice initiative. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 1181-1186.	1.2	29
33	Identifying priority areas for research into the diagnosis, treatment and prevention of cellulitis (erysipelas): results of a James Lind Alliance Priority Setting Partnership. <i>British Journal of Dermatology</i> , 2017, 177, 541-543.	1.5	27
34	How should minimally important change scores for the Patient-Oriented Eczema Measure be interpreted? A validation using varied methods. <i>British Journal of Dermatology</i> , 2018, 178, 1135-1142.	1.5	26
35	Standardized reporting of the Eczema Area and Severity Index (EASI) and the Patient-Oriented Eczema Measure (POEM): a recommendation by the Harmonising Outcome Measures for Eczema (HOME) Initiative. <i>British Journal of Dermatology</i> , 2018, 179, 540-541.	1.5	25
36	Randomized controlled trial of topical corticosteroid and home-based narrowband ultraviolet B for active and limited vitiligo: results of the H&Light Vitiligo Trial*. <i>British Journal of Dermatology</i> , 2021, 184, 828-839.	1.5	25

#	ARTICLE	IF	CITATIONS
37	A randomized controlled trial to compare the safety and effectiveness of doxycycline (200Âmg daily) with oral prednisolone (0Â5ÂmgÂkgÂ~1 daily) for initial treatment of bullous pemphigoid: a protocol for		

#	ARTICLE	IF	CITATIONS
55	Protocol for an outcome assessor-blinded pilot randomised controlled trial of an ion-exchange water softener for the prevention of atopic eczema in neonates, with an embedded mechanistic study: the Softened Water for Eczema Prevention (SOFTER) trial. <i>BMJ Open</i> , 2019, 9, e027168.	1.9	8
56	Two-by-two factorial randomised study within a trial (SWAT) to evaluate strategies for follow-up in a randomised prevention trial. <i>Trials</i> , 2020, 21, 529.	1.6	8
57	Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting. <i>British Journal of Dermatology</i> , 2020, 185, 139.	1.5	7
58	Skincare interventions in infants for preventing eczema and food allergy. <i>The Cochrane Library</i> , 2020, , .	2.8	7
59	Supporting families managing childhood eczema: developing and optimising eczema care online using qualitative research. <i>British Journal of General Practice</i> , 2022, 72, e378-e389.	1.4	7
60	TEST (Trial of Eczema allergy Screening Tests): protocol for feasibility randomised controlled trial of allergy tests in children with eczema, including economic scoping and nested qualitative study. <i>BMJ Open</i> , 2019, 9, e028428.	1.9	6
61	Different strategies for using topical corticosteroids in people with eczema. <i>The Cochrane Library</i> , 0, , .	2.8	6
62	An economic evaluation of the randomized controlled trial of topical corticosteroid and home-based narrowband ultraviolet B for active and limited vitiligo (the HILIGHT Vitiligo Trial)*. <i>British Journal of Dermatology</i> , 2021, 184, 840-848.	1.5	6
63	Measurement properties of patient-reported outcome measures for eczema control: a systematic review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1987-1993.	2.4	6
64	Eczema Care Online: development and qualitative optimisation of an online behavioural intervention to support self-management in young people with eczema. <i>BMJ Open</i> , 2022, 12, e056867.	1.9	6
65	Patients' understanding of cellulitis and their information needs: a mixed-methods study in primary and secondary care. <i>British Journal of General Practice</i> , 2019, 69, e279-e286.	1.4	5
66	A programme of research to set priorities and reduce uncertainties for the prevention and treatment of skin disease. <i>Programme Grants for Applied Research</i> , 2016, 4, 1-488.	1.0	5
67	Clinical examination for hyperlinear palms to determine filaggrin genotype: A diagnostic test accuracy study. <i>Clinical and Experimental Allergy</i> , 2021, 51, 1421-1428.	2.9	5
68	Impact of childhood atopic dermatitis on life decisions for caregivers and families. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	2.4	5
69	Clearing up misunderstandings around core outcomes for atopic dermatitis. <i>British Journal of Dermatology</i> , 2015, 173, 623-624.	1.5	3
70	Do patient characteristics matter when calculating sample size for eczema clinical trials?. <i>Skin Health and Disease</i> , 2021, 1, e42.	1.5	3
71	Scoping the international impact from four independent national dermatology trials. <i>Clinical and Experimental Dermatology</i> , 2021, 46, 657-662.	1.3	2
72	The BLISTER study: possible overestimation of tetracycline efficacy – Authors' reply. <i>Lancet</i> , The, 2017, 390, 735-736.	13.7	1

#	ARTICLE	IF	CITATIONS
73	Long-term oral prednisolone exposure in primary care for bullous pemphigoid: population-based study. British Journal of General Practice, 2021, 71, e904-e911.	1.4	1
74	Reply. Journal of Allergy and Clinical Immunology, 2015, 135, 1664.	2.9	0
75	Developing a Dermatology Clinical Trials Network for Improved Therapeutics and Clinical Outcomes Research. Current Dermatology Reports, 2015, 4, 90-95.	2.1	0
76	Using electronic health records to inform trial feasibility in a rare autoimmune blistering skin disease in England. BMC Medical Research Methodology, 2021, 21, 22.	3.1	0
77	Spleen to liver stiffness ratio significantly differs between ALD and HCV and predicts disease-specific complications. Zeitschrift Fur Gastroenterologie, 2019, 57, .	0.5	0
78	Prescribing and using vitiligo treatments â€“ lessons from a nested Process Evaluation within the <scp>Hlâ€Light</scp> Vitiligo Randomised Controlled Trial. Clinical and Experimental Dermatology, 2022, , .	1.3	0
79	Towards a better understanding of outcome measurement instruments for atopic eczema. British Journal of Dermatology, 2018, 179, 246-247.	1.5	0